CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 13 enrolled
Drug / intervention
Blood draw for future biomarker analysisother
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03784898
NCT03784898Phase 4Completed
CompareCT.gov

Collection of Blood Samples From Patients With Relapsing Forms of Multiple Sclerosis (RMS) Who Have Developed Immune Thrombocytopenic Purpura (ITP) After LEMTRADA® Treatment

Genzyme, a Sanofi Company·interventional·Posted Dec 24, 2018·Updated Mar 28, 2022

In Brief

A Phase 4 clinical trial evaluating Blood draw for future biomarker analysis for Multiple Sclerosis. Completed, enrolled 13 participants across 1 site.

Detailed Summary

Primary Objective: To collect blood samples in a new cohort of Relapsing Forms of Multiple Sclerosis (RMS) participants who had developed immune thrombocytopenic purpura (ITP) after LEMTRADA treatment, for future Deoxyribonucleic acid (DNA) analysis as part of a global biomarker project assessing pre-identified candidate single nucleotide polymorphisms (SNPs) associated to the development of ITP after LEMTRADA treatment in RMS participants.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMultiple Sclerosis
CountriesUnited States
Collaborators--

Timeline

Phase 4CompletedFinished
20192020202120222023202420252026
First PostedDec 24, 2018
Enrollment StartFeb 8, 2019
Primary CompletionDec 11, 2019
TodayJul 2, 2026
Enrollment to primary: 10 monthsPosted 7.5 years ago

Interventions

Blood draw for future biomarker analysisother

Each participant was required to undergo blood draw for future genetic testing and biomarker analysis as mentioned in the informed consent form (ICF).